Thermo Fisher Scientific has completed the sale of its microbiology business to European private equity firm Astorg, with the unit now operating as an independent company serving clinical, food-safety and pharmaceutical markets. The transaction—announced in April—was priced at about $1.075 billion, including cash and a $50 million seller note.